# Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Aditya Bardia,Ian E. Krop,Takahiro Kogawa,Dejan Juric,Anthony W. Tolcher,Erika Hamilton,Toru Mukohara,Aaron Lisberg,Toshio Shimizu,Alexander I. Spira,Junji Tsurutani,Senthil Damodaran,Kyriakos P. Papadopoulos,Jonathan Greenberg,Fumiaki Kobayashi,Hong Zebger‐Gong,Rie Wong,Yui Kawasaki,Tadakatsu Nakamura,Funda Meric‐Bernstam |
| Citations | 170 |
| DOI | 10.1200/jco.23.01909 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1200/jco.23.01909 |
| OpenAlex ID | https://openalex.org/W4395027993 |
| PMID | 38652877 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Aaron Lisberg](https://scholariq.org/researchers/aaron-lisberg/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.